SLC2A10: A Protein Involved in Brain Function and Potential Drug Target

Target Name: SLC2A10

NCBI ID: G81031

SLC2A10

SLC2A10: A Protein Involved in Brain Function and Potential Drug Target

SLC2A10 (Sodium-Glucose cotransporter 2, type 10) is a protein that is expressed in the brain and is involved in the transport of glucose into the cell. It is a key component of the blood-brain barrier, which is a barrier that separates the brain from the blood and helps to protect it from harmful substances. SLC2A10 is also expressed in other tissues and is involved in a number of physiological processes in the body.

SLC2A10 is a drug target (or biomarker) because it can be used to study the effects of drugs on the brain and to identify new treatments for neurological disorders. For example, SLC2A10 has been used to study the effects of drugs on memory and cognitive function in both humans and animals. Additionally, SLC2A10 has been used to identify new biomarkers for neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

SLC2A10 is also of interest as a potential therapeutic target for the treatment of neurological disorders because it is involved in the delivery of glucose into the brain and is a key component of the blood-brain barrier. This means that drugs that can increase the amount of SLC2A10 available in the brain could potentially be effective in treating neurological disorders. For example, drugs that increase the activity of SLC2A10 have been shown to be effective in animal models of Alzheimer's disease and Parkinson's disease.

In addition to its potential therapeutic uses, SLC2A10 is also of interest as a potential biomarker for neurological disorders. The blood-brain barrier is a very difficult barrier to cross, and it is not easy to study the effects of drugs on the brain. However, SLC2A10 is expressed in the brain and can be used to study the effects of drugs on this protein. This makes it an attractive tool for identifying new biomarkers for neurological disorders.

Overall, SLC2A10 is a protein that is expressed in the brain and is involved in the transport of glucose into the cell. It is also involved in a number of physiological processes in the body and is a potential drug target (or biomarker) for the treatment of neurological disorders. Further research is needed to fully understand the role of SLC2A10 in the brain and to identify its potential as a therapeutic target or biomarker.

Protein Name: Solute Carrier Family 2 Member 10

Functions: Facilitative glucose transporter required for the development of the cardiovascular system

The "SLC2A10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets